Patents by Inventor Zhijian J. Chen

Zhijian J. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7452977
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I?B?, I?B? kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-?B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: November 18, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Zhijian J. Chen
  • Patent number: 6787346
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I&kgr;B&agr;, I&kgr;B&agr; kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-&kgr;B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: September 7, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Zhijian J. Chen
  • Publication number: 20040161814
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I&kgr;B&agr;, I&kgr;B&agr; kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-&kgr;B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
    Type: Application
    Filed: March 25, 2004
    Publication date: August 19, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Zhijian J. Chen
  • Publication number: 20030073097
    Abstract: Proteins in the IKK and JNK signaling pathways, such as NF&kgr;B, are involved in the regulation of inflammatory diseases. Through phosphorylation and polyubiquitination, I&kgr;B proteins which sequester NF&kgr;B in the cytoplasm, are degraded by the ubiquitin-proteasome pathway releasing NF&kgr;B to the nucleus where it is activated. The present invention provides methods utilizing the composition of proteins in the IKK, JNK and ubiquitin-proteasome pathways such as, TRAF6 or TRAF2 (E3-ubiquitin protein ligase), TRIKA1/Uev1A/Ubc13 complex (E2-ubiquitin conjugating enzyme), and TRIKA2/TAK1 (protein kinase), in screening for candidate modulators involved in activation of the IKK and JNK pathways. The application further provides methods of utilizing the candidate modulators as drug therapeutics against inflammatory and immune diseases.
    Type: Application
    Filed: October 11, 2001
    Publication date: April 17, 2003
    Inventors: Zhijian J. Chen, Li Deng
  • Publication number: 20020168740
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I&kgr;B&agr;, I&kgr;B&agr; kinase. In particular, the present invention relates to the purified kinase, purified polypeptide subunits of the kinase, nucleic acid molecules coding for the purified polypeptide subunits; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to the kinase or its polypeptide subunits; hybridomas containing the antibodies; nucleic acid probes for the detection of the nucleic acid encoding the kinase; a method of detecting nucleic acids encoding the kinase or polypeptides of the kinase in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-&kgr;B.
    Type: Application
    Filed: September 24, 1999
    Publication date: November 14, 2002
    Inventor: ZHIJIAN J. CHEN
  • Publication number: 20020151022
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I&kgr;B&agr;, I&kgr;B&agr; kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-&kgr;B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
    Type: Application
    Filed: January 17, 2002
    Publication date: October 17, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Zhijian J. Chen
  • Patent number: 6107073
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I.kappa.B.alpha., I.kappa.B.alpha. kinase. In particular, the present invention relates to the purified- kinase, purified polypeptide subunits of the kinase, nucleic acid molecules coding for the purified polypeptide subunits; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to the kinase or its polypeptide subunits; hybridomas containing the antibodies; nucleic acid probes for the detection of the nucleic acid encoding the kinase; a method of detecting nucleic acids encoding the kinase or polypeptides of the kinase in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-.kappa.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: August 22, 2000
    Assignee: LeukoSite, Inc.
    Inventor: Zhijian J. Chen